10,745 Shares in Mirum Pharmaceuticals, Inc. $MIRM Acquired by Diversified Trust Co

Diversified Trust Co bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 10,745 shares of the company’s stock, valued at approximately $993,000.

Other institutional investors also recently made changes to their positions in the company. Janus Henderson Group PLC boosted its stake in Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after acquiring an additional 1,067,722 shares during the last quarter. State Street Corp grew its stake in Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after buying an additional 797,088 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after acquiring an additional 672,118 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in shares of Mirum Pharmaceuticals by 709.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after buying an additional 536,674 shares during the last quarter. Finally, Voloridge Investment Management LLC raised its position in shares of Mirum Pharmaceuticals by 2,116.6% during the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after buying an additional 371,999 shares in the last quarter.

Analysts Set New Price Targets

Several research firms recently commented on MIRM. Royal Bank Of Canada increased their target price on shares of Mirum Pharmaceuticals from $128.00 to $142.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Citizens Jmp increased their price target on shares of Mirum Pharmaceuticals from $140.00 to $146.00 and gave the stock a “market outperform” rating in a research note on Monday, June 15th. Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Monday, June 15th. Evercore restated an “outperform” rating and set a $138.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, Wall Street Zen cut Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Mirum Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $139.80.

Mirum Pharmaceuticals Trading Up 3.2%

NASDAQ:MIRM opened at $111.19 on Wednesday. The stock has a market capitalization of $6.78 billion, a PE ratio of -8.17 and a beta of 0.50. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $47.89 and a fifty-two week high of $114.99. The business’s 50-day simple moving average is $99.19 and its 200-day simple moving average is $92.93.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). The firm had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company’s revenue was up 43.3% compared to the same quarter last year. During the same period last year, the company earned ($0.30) EPS. Sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $101.95, for a total value of $264,458.30. Following the transaction, the senior vice president directly owned 5,835 shares of the company’s stock, valued at $594,878.25. This trade represents a 30.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. The trade was a 13.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,594 shares of company stock valued at $3,608,758 over the last quarter. 8.32% of the stock is owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.